Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion 44: zongertinib + platinum-based chemotherapy ± pembrolizumab in HER2-mutant advanced non-squamous NSCLC
jRCT2051260082Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of zongertinib discontinuation or prolonged interruption due to treatment-related adverse events in first 2 cycles. Started Jun 2026; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051260082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260082.